Global biotech manufacturer scaling clinical programs and reimbursement operations
Biogen operates a diversified biotech engine across research, manufacturing, and commercialization—with hiring concentrated in healthcare, operations, and marketing roles rather than pure R&D. The tech stack is heavy on analytical and manufacturing control systems (SCADA, PLC, DeltaV, OSIsoft PI) alongside pharma-standard tools (Veeva CRM, SAS, LC-MS), reflecting operations-intensive scale. Active projects cluster around reimbursement strategy, clinical development acceleration, and treatment-access barriers, suggesting a company navigating complex regulatory and payer dynamics rather than pure discovery.
Notable leadership hires: Insights Analytics Director, Associate Scientific Director, Scientific Director, Clinical Pharmacology, Supply Chain Quality Lead, Medical Director
Biogen is a publicly traded biotechnology company headquartered in Cambridge, Massachusetts, with approximately 7,000 employees and manufacturing operations in North Carolina and Switzerland. The company develops first-in-class treatments across multiple therapeutic areas, with a commercial footprint spanning 30 countries via direct affiliates and distribution partners across 50+ additional territories. Core operations span research (Cambridge), manufacturing (North Carolina, Solothurn), and a distributed commercial and support organization. Current strategic focus includes accelerating clinical programs for new indications, improving launch readiness, and addressing reimbursement and regulatory compliance challenges in global markets.
Core tools include SQL, Python, R, Oracle, Salesforce, Veeva CRM, Power BI, Tableau, SAS, and specialized pharma/manufacturing systems: SCADA, PLC, DeltaV, OSIsoft PI, FactoryTalk, and LC-MS. Okta and SailPoint handle identity management.
Active projects include accelerating clinical development for new transplant indications, developing territory business plans, refining reimbursement and payer strategies, improving launch readiness, and enhancing treatment-access pathways. Compliance with global pharmacovigilance and cGMP regulations is a priority.
Other companies in the same industry, closest in size